Brazil & Latin America

Building advanced therapy capacity from Brazil

Connecting NK/CAR-NK science, local manufacturing capacity, oncology networks, regulatory strategy and public-health access planning.

01 // Why Brazil

A meaningful position in the global ecosystem.

Oncology burden
Large patient populations across multiple oncology indications.
Mature centers
Established clinical research centers in selected disease areas.
Evolving regulation
A growing advanced therapy regulatory framework.
Local capacity
Need for domestic manufacturing and logistics solutions.
Cost realities
Opportunity to reduce dependency on imported high-cost therapies.
Translational reach
Access models that span private and public health pathways.
02 // ANVISA-Ready Thinking

Regulatory-aware development.

BioNK’s development planning incorporates awareness of Produtos de Terapia Avançada frameworks, clinical development authorization, GMP/BPF and GCP/BPC expectations, GLP/BPL where applicable, pharmacovigilance, and long-term follow-up planning for gene-modified products where relevant.

Specific regulatory references are addressed in confidential development documentation and are not cited in detail on this public website.

03 // Access Without Overclaiming

Responsible access planning.

BioNK evaluates public and private access pathways with attention to health-economic evidence, manufacturing capacity, logistics, clinical-site readiness and reimbursement feasibility.

We do not claim incorporation into public health systems and we do not promise reimbursement, regulatory approval or commercial availability.